Skip to main content
Top
Published in: Medical Oncology 4/2011

01-12-2011 | Original Paper

Targeting integrin-linked kinase increases apoptosis and decreases invasion of myeloma cell lines and inhibits IL-6 and VEGF secretion from BMSCs

Authors: Xiaofang Wang, Zhiqing Zhang, Cheng Yao

Published in: Medical Oncology | Issue 4/2011

Login to get access

Abstract

In this study, we investigated ILK expression in myeloma cell lines U266 and H929 kept in suspension and cocultured with BMSCs, and studied the pharmacologic inhibitors of ILK on the apoptosis, invasive potential of myeloma cell lines, and production of pro-angiogenic factors of bone marrow stromal cells. We found that ILK protein was expressed in U266 and H929 cells and kinase activity was elevated when cocultured with BMSCs. ILK inhibitor QLT0267 reduced ILK kinase activity and increased apoptosis both in myeloma cell lines kept in suspension and cocultured with BMSCs. ILK inhibition by ILK inhibitor decreased the in vitro invasive capability of myeloma cell lines. In addition, QLT0267 significantly decreased VEGF and IL-6 secretion in BMSCs in a dose-dependent fashion. The results indicated that inhibition of ILK may provide a potential target for myeloma therapy.
Literature
1.
go back to reference Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129:776–83.PubMedCrossRef Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129:776–83.PubMedCrossRef
2.
go back to reference Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24:929–36.PubMedCrossRef Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24:929–36.PubMedCrossRef
3.
go back to reference Rajkumar SV, Jacobus S, Callander N, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2007;25:LBA8025. (Meeting Abstracts). Rajkumar SV, Jacobus S, Callander N, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2007;25:LBA8025. (Meeting Abstracts).
4.
go back to reference Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood. 2005;105:1383–95.PubMedCrossRef Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood. 2005;105:1383–95.PubMedCrossRef
5.
go back to reference Pagnucco G, Cardinale G, Gervasi F. Targeting multiple myeloma cells and their bone marrow microenvironment. Ann N Y Acad Sci. 2004;1028:390–9.PubMedCrossRef Pagnucco G, Cardinale G, Gervasi F. Targeting multiple myeloma cells and their bone marrow microenvironment. Ann N Y Acad Sci. 2004;1028:390–9.PubMedCrossRef
6.
go back to reference Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607–18.PubMedCrossRef Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607–18.PubMedCrossRef
7.
go back to reference Koul D, Shen R, Bergh S, Lu Y, de Groot JF, et al. Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther. 2005;4:1681–8.PubMedCrossRef Koul D, Shen R, Bergh S, Lu Y, de Groot JF, et al. Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther. 2005;4:1681–8.PubMedCrossRef
8.
go back to reference Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, et al. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res. 2006;66:393–403.PubMedCrossRef Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, et al. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res. 2006;66:393–403.PubMedCrossRef
9.
go back to reference Younes MN, Kim S, Yigitbasi OG, Mandal M, Jasser SA, et al. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther. 2005;4:1146–56.PubMedCrossRef Younes MN, Kim S, Yigitbasi OG, Mandal M, Jasser SA, et al. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther. 2005;4:1146–56.PubMedCrossRef
10.
go back to reference Wu C, Keightley SY, Leung-Hagesteijn C, Radeva G, Coppolino M, et al. Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity. J Biol Chem. 1998;273:528–36.PubMedCrossRef Wu C, Keightley SY, Leung-Hagesteijn C, Radeva G, Coppolino M, et al. Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity. J Biol Chem. 1998;273:528–36.PubMedCrossRef
11.
go back to reference Ito R, Oue N, Zhu X, Yoshida K, Nakayama H, et al. Expression of integrin-linked kinase is closely correlated with invasion and metastasis of gastric carcinoma. Virchows Arch. 2003;442:118–23.PubMed Ito R, Oue N, Zhu X, Yoshida K, Nakayama H, et al. Expression of integrin-linked kinase is closely correlated with invasion and metastasis of gastric carcinoma. Virchows Arch. 2003;442:118–23.PubMed
12.
go back to reference Mohanam S, Sawaya R, McCutcheon I, Ali-Osman F, Boyd D, et al. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res. 1993;53:4143–7.PubMed Mohanam S, Sawaya R, McCutcheon I, Ali-Osman F, Boyd D, et al. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res. 1993;53:4143–7.PubMed
13.
go back to reference Wong RP, Ng P, Dedhar S, Li G. The role of integrin-linked kinase in melanoma cell migration, invasion, and tumor growth. Mol Cancer Ther. 2007;6(6):1692–700.PubMedCrossRef Wong RP, Ng P, Dedhar S, Li G. The role of integrin-linked kinase in melanoma cell migration, invasion, and tumor growth. Mol Cancer Ther. 2007;6(6):1692–700.PubMedCrossRef
14.
go back to reference Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma. Cancer Res. 2001;61:3071–6.PubMed Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma. Cancer Res. 2001;61:3071–6.PubMed
15.
go back to reference Gupta D, Treon SP, Shima Y, Hideshima T, Podar K. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15:1950–61.PubMedCrossRef Gupta D, Treon SP, Shima Y, Hideshima T, Podar K. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15:1950–61.PubMedCrossRef
16.
go back to reference Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor in the pathogenesis of human multiple myeloma: therapeutic applications. Oncogene. 2001;20:4519–27.PubMedCrossRef Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor in the pathogenesis of human multiple myeloma: therapeutic applications. Oncogene. 2001;20:4519–27.PubMedCrossRef
Metadata
Title
Targeting integrin-linked kinase increases apoptosis and decreases invasion of myeloma cell lines and inhibits IL-6 and VEGF secretion from BMSCs
Authors
Xiaofang Wang
Zhiqing Zhang
Cheng Yao
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9616-y

Other articles of this Issue 4/2011

Medical Oncology 4/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.